Equity
€1.4m ▲ 19.8%
ANURO has made a profit without a break since 2018.
ANURO
Lifetime
20 annual accounts with figures on one time axispeak €605,646 (2024)
€367,404▼ 39.3%
lowest -€19,219 (2017)
€232,859▼ 41.8%
peak €1.4m (2025)
€1.4m▲ 19.8%
€240,263▼ 38.3%
Board3 names since 2005
2 directors and 1 other
Documentsfilings and deeds
23-08-202623 days late
2025micro format
Gross margin from €605,646 to €367,404Result from €400,263 to €232,859Equity from €1.2m to €1.4mDebts from €389,147 to €240,263Cash from €398,583 to €169,269
Key points
from the 2025 annual accountsResult
€232,859 ▼ 41.8%
The result fell in 2025 from €400,263 to €232,859.
Turnover
≈ €560,000 estimated
The micro format states no turnover.
Liquidity
2.73 was 2.16 in 2024
Short-term debts fell from €228,169 to €215,793.
Filings
20 annual accounts since 2006
Seven of the last ten came late. The 2020 accounts came latest: 123 days after the end of the period.
Position in the sector
€1.4m
More equity than 95% of companies in human health. Sector median €125,064 · 21,313 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 20,124 companies had the same profile as ANURO has now. Each dot stands for 51 companies, two years later.
95.1%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 20,124 companies, not a prediction for ANURO. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, since 28-11-2005
Director, since 28-11-2005
- 50 sharesdeed of 06-12-2023
- 50 sharesdeed of 06-12-2023
Recent changes
Purpose change · Amendment of the articles · Legal-form change · Resignations & appointments
Resignations: (director) and (director) · Appointments: (director) and (director) · “De uitoefening door de artsen-aandeelhouders van de geneeskunde onder meer - doch niet uitsluitend of…” (deed in Dutch) · General meeting of 30-11-2023 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0877548607
Reappointments: (manager) and (manager)
General meeting of 23-11-2015 · Gazette deed
Incorporation
published on 07-12-2005 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| ANURO Schilde | €1.7m | €367,404 | 85.4% | - |
| Dokters Buelens - Clerckx Lier | €1.7m | €370,031 | 99.6% | 0 |
| Dokter K. Anseeuw Sint-Katelijne-Waver | €1.6m | €384,791 | 41.8% | - |
| DR.SEMERARO,cardiologie.DR.FRANKEFORT,OPHTALMOLOGIE Mechelen | €1.6m | €382,707 | 59.7% | - |
| DR.COREMANS EN DR. NOWÉ Willebroek | €1.8m | €357,747 | 90.5% | - |
| Dokter Ann Aerts Westerlo | €1.6m | €401,989 | 89.3% | - |
| LIMON Edegem | €1.7m | €355,601 | 71.6% | - |
These companies have the same main activity as ANURO: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €1.6m and €1.8m, founded between 2003 and 2007.
Official details
Source: KBO- Status
- Active since 28-11-2005Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.304.027.3402970 Schilde, since 28-11-2005
- Financial year end
- 31 December
- Peppol
- Reachable since 24-11-2023
Insights on ANURO
ANURO files the micro format. That format states no turnover. The gross margin rose from €353,711 in 2006 to €367,404 in 2025.
The balance sheet grew most in 2017 through fixed assets, financed with long-term debt.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about ANURO
- What is the company number of ANURO?
- The company number of ANURO is 0877.548.607. The VAT number is the same number with BE in front: BE 0877.548.607.
- Where is ANURO based?
- The registered office is at Jagerande 2, 2970 Schilde.Company details
- What does ANURO do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of ANURO?
- ANURO is a private limited company (BV).
- When was ANURO founded?
- ANURO was founded on 28-11-2005.
- Is ANURO still active?
- Yes, ANURO is an active enterprise in the KBO register.
- What is the turnover of ANURO?
- The turnover in financial year 2025 is ≈ €560,000. This figure is estimated from the gross margin of €367,404 and 30 comparable companies (NACE 86220). It probably lies between €500,000 and €770,000.Financials
- Is ANURO profitable?
- In financial year 2025, ANURO made a profit of €232,859.
- Where can I find the annual accounts of ANURO?
- ANURO filed 20 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ANURO due?
- ANURO must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.